Skip to content

Dose-averaged Linear Energy Transfer (LETd)-Guided Biological Dose Painting in Carbon Ion Radiotherapy (CIRT) for Locally Advanced Pancreatic Cancer (LAPC): A Dosimetric and Prospective Clinical Feasibility Study

Dose-averaged Linear Energy Transfer (LETd)-Guided Biological Dose Painting in Carbon Ion Radiotherapy (CIRT) for Locally Advanced Pancreatic Cancer (LAPC): A Dosimetric and Prospective Clinical Feasibility Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107506
Enrollment
Unknown
Registered
2025-08-13
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

locally advanced pancreatic cancer

Interventions

LETd-guided biological dose painting group:LETd-guided biological dose painting carbon ion radiotherapy

Sponsors

The Clinical Technology Research And Development Center of Shanghai Proton and Heavy Ion Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Ability to comply with the study protocol and provide written informed consent; 2. Aged between 18 and 80 years; 3. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC); 4. Defined as locally advanced unresectable diseases according to the NCCN Guidelines Pancreatic Adenocarcinoma Guidelines (Version 2.2025); 5. No evidence of distant metastasis based on imaging examinations; 6. The primary lesion or positive lymph nodes do not invade the gastrointestinal tract; 7. ECOG performance status score of 0–1; 8. Adequate bone marrow, as well as hepatic and renal function;

Exclusion criteria

Exclusion criteria: 1. Tumor invaded adjacent gastrointestinal structures; 2. History of prior radiotherapy to the upper abdomen or radioactive seed implantation that may lead to overlapping radiation fields; 3. Previous local therapies for pancreatic cancer such as high-intensity focused ultrasound or irreversible electroporation, etc. 4. Presence of internal implanted that may malfunction under high-energy radiation exposure or interfere with radiation dose distribution; 5. Unable to lie prone for more than 15 minutes on the immobilization device; 6. Prior chemotherapy regimen not including gemcitabine or fluoropyrimidines; 7. Presence of active gastric and/or duodenal ulcers, active upper abdominal infections, active inflammatory bowel disease, or other severe comorbidities; 8. History of other malignancies;

Design outcomes

Primary

MeasureTime frame
Acute toxicity;

Secondary

MeasureTime frame
Acute toxicity;

Countries

China

Contacts

Public ContactZheng Wang

The Clinical Technology Research And Development Center of Shanghai Proton and Heavy Ion Center

zheng.wang@sphic.org.cn+86 21 3829 6666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026